Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 05/04/21
Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in DiabetesBusiness Wire • 04/20/21
Genprex presents positive preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meetingProactive Investors • 04/12/21
Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual MeetingBusiness Wire • 04/12/21
Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the MediterraneanBusiness Wire • 04/05/21
Genprex to present preclinical data for lung cancer drug REQORSA at American Association for Cancer Research meetingProactive Investors • 03/30/21
Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual MeetingBusiness Wire • 03/30/21
Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29Business Wire • 03/24/21
Genprex announces $25 million registered direct offering priced at-the-marketProactive Investors • 02/09/21
Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without WarrantsBusiness Wire • 02/09/21
Genprex forms Clinical Advisory Board to support its oncology and diabetes development programsProactive Investors • 02/08/21
Genprex to Present at the Virtual Investor Conference Small and Microcap Showcase on February 4Business Wire • 01/27/21
Genprex to Present its Cutting-Edge Gene Therapies at the MoneyShow Accredited Investors Virtual ExpoBusiness Wire • 01/21/21
Genprex Achieves Major Manufacturing Milestone for REQORSA™ Immunogene Therapy for Upcoming Trials to Treat Non-Small Cell Lung CancerBusiness Wire • 01/13/21
Genprex, Inc. Announces Closing Of $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Without WarrantsBusiness Wire • 12/24/20
Genprex, Inc. Announces $12 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules, Without WarrantsBusiness Wire • 12/22/20
Genprex's Leading Drug Candidate Is Currently Being Developed As A Treatment For Lung CancerBenzinga • 12/22/20
Genprex Completes Manufacturing Scale-Up for Clinical-Grade Production of REQORSA™ Immunogene Therapy for Upcoming Acclaim-1 and Acclaim-2 Clinical Trials For Lung CancerBusiness Wire • 12/22/20